secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTENSITY THERAPEUTICS, INC. (INTS)
CIK:        0001567264
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001567264-25-000078
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intensity Therapeutics raises $11.3M, extends cash runway to H2 2026; Q2 net loss narrows to $2.5M
--------------------------------------------------------------------------------

- Net proceeds of ~$10.1M from two public offerings and ATM; cash runway now into H2 2026.
- Q2 2025 net loss $2.5M vs $5.0M in Q2 2024; R&D expense fell to $1.5M from $3.6M.
- INVINCIBLE-3 (soft tissue sarcoma) enrollment paused in March after 23 patients; existing patients continue dosing.
- INVINCIBLE-4 (triple-negative breast cancer) recruiting in France and Switzerland; EMA authorized initiation.
- INT230-6 showed 100% complete response in preclinical MPNST models; company believes Nasdaq compliance restored.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567264/000156726425000078/0001567264-25-000078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567264/000156726425000078/intensity-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001567264-25-000078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer